Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
160 studies found for:    Open Studies | "Lupus Erythematosus, Systemic"
Show Display Options
Rank Status Study
21 Unknown  Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.
Conditions: Systemic Lupus Erythematosus;   Sleep Disorders
Interventions: Procedure: Aerobic Exercise;   Other: Control Group
22 Recruiting Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Conditions: Systemic Lupus Erythematosus;   Antiphospholipid Syndrome
Intervention:
23 Recruiting Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Other: therapeutic education
24 Recruiting A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Ustekinumab IV;   Drug: Placebo Infusion;   Drug: Placebo SC;   Drug: Ustekinumab SC;   Other: Concomitant Medication
25 Not yet recruiting Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
26 Recruiting Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: prednisone discontinuation
27 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
28 Not yet recruiting Evaluation and Prediction of Relapse Risk in Patients With Stable Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Other: Drug free;   Drug: HCQ;   Drug: GC+HCQ
29 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
30 Unknown  Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
Conditions: Antiphospholipid Syndrome;   Thrombophilia Due to Antiphospholipid Antibody;   Systemic Lupus Erythematosus
Intervention: Other: Phlebotomy
31 Unknown  Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
Conditions: Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Ankylosing Spondylitis
Intervention:
32 Recruiting A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus;   Healthy
Interventions: Drug: JNJ-55920839;   Drug: Placebo
33 Recruiting Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: ACT-334441;   Drug: Placebo
34 Recruiting Phase Ib Study of SC Milatuzumab in SLE
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic;   Lupus Vasculitis, Central Nervous System;   Lupus Nephritis
Interventions: Drug: milatuzumab;   Drug: Placebo
35 Recruiting A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
36 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
37 Recruiting Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
38 Recruiting Systemic Lupus Erythematosus in Gullah Health
Condition: Systemic Lupus Erythematosus
Intervention:
39 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
40 Not yet recruiting Acthar SLE (Systemic Lupus Erythematosus)
Conditions: Systemic Lupus Erythematosus (SLE);   Repository Corticotropin Injection
Interventions: Drug: Acthar low dose (40 U);   Drug: Acthar high dose (80 U)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years